Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
Date:2/21/2013

THE WOODLANDS, Texas, Feb. 21, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2012.

"We continued to make significant progress in the development of our pipeline in 2012, highlighted by positive results from clinical studies of LX4211 in diabetes and telotristat etiprate in carcinoid syndrome," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon. "We are pleased to have commenced the Phase 3 program for telotristat etiprate in carcinoid syndrome, and continue to progress in our preparations for LX4211 Phase 3 initiation. We also look forward to significant proof-of-concept results in irritable bowel syndrome (IBS) with LX1033, ulcerative colitis with telotristat etiprate, and type 1 diabetes with LX4211 in 2013."

Key Developments in 2012

  • LX4211:  Lexicon reported positive results from a 12-week Phase 2b clinical trial of LX4211, a dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1 and SGLT2) in patients with type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy. LX4211 treatment produced substantial, dose-dependent and statistically-significant reductions in hemoglobin A1c (HbA1c), with patients in the high dose (400 mg QD) LX4211 treatment arm having a mean HbA1C reduction from baseline of 0.95 percent (p<0.001). In patients randomized to placebo, HbA1C decreased by 0.09 percent. LX4211 treatment also produced significant reduct
    '/>"/>

  • SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Lexicon To Present At The BIO CEO & Investor Conference
    2. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
    3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
    4. Lexicon to Provide Third Quarter 2012 Financial Results
    5. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
    6. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
    7. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
    8. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
    9. Lexicon to Provide Second Quarter 2012 Financial Results
    10. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
    11. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/3/2015)... (NASDAQ: CYTR ), a biopharmaceutical research and development ... the three months ended June 30, 2015, and also ... for its clinical development programs. "The second ... Enrollment in our ongoing pivotal global Phase 3 clinical ... on track to be completed in the first quarter ...
    (Date:8/3/2015)... , Aug. 3, 2015 Merrimack Pharmaceuticals, ... will host its Second Quarter 2015 Investor Conference Call ...    The call will cover an update ... second quarter 2015 financials. A press release detailing the ... issued the afternoon of Monday, August 10. Investors and ...
    (Date:8/3/2015)...  Celsion Corporation (NASDAQ: CLSN ) announced ... call to discuss its second quarter 2015 financial ... programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation ... TheraPlas™ and TheraSilence™, in immunotherapy and RNA delivery ... 2015. To participate in the call, interested parties ...
    Breaking Medicine Technology:CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Celsion Corporation to Hold Second Quarter 2015 Financial Results Conference Call on Monday, August 10, 2015 2
    ... Nov. 17, 2010 /PRNewswire-FirstCall/ -- ... ) today announced the pricing of an underwritten public offering ... price of $4.40 per share.  The offering is expected to ... closing conditions.  In addition, AVANIR has granted the underwriters a ...
    ... BEIJING, Nov. 17, 2010 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... leading China-based advanced in-vitro diagnostic ("IVD") company, today announced ... ended September 30, 2010 ("2Q FY2010"). ... Revenues increased by 21.5% year-over-year to ...
    Cached Medicine Technology:AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock 3China Medical Technologies Reports Second Fiscal Quarter Financial Results 2China Medical Technologies Reports Second Fiscal Quarter Financial Results 3China Medical Technologies Reports Second Fiscal Quarter Financial Results 4China Medical Technologies Reports Second Fiscal Quarter Financial Results 5China Medical Technologies Reports Second Fiscal Quarter Financial Results 6China Medical Technologies Reports Second Fiscal Quarter Financial Results 7China Medical Technologies Reports Second Fiscal Quarter Financial Results 8China Medical Technologies Reports Second Fiscal Quarter Financial Results 9China Medical Technologies Reports Second Fiscal Quarter Financial Results 10China Medical Technologies Reports Second Fiscal Quarter Financial Results 11China Medical Technologies Reports Second Fiscal Quarter Financial Results 12China Medical Technologies Reports Second Fiscal Quarter Financial Results 13China Medical Technologies Reports Second Fiscal Quarter Financial Results 14
    (Date:8/4/2015)... Louis, MO (PRWEB) , ... August 04, 2015 ... ... attorneys handling national talcum powder lawsuits filed against Johnson & Johnson report that ... Talcum powder lawyers provide regular news updates and cancer warning information ...
    (Date:8/4/2015)... ... August 04, 2015 , ... ... digital press at its Denver facility that will usher in a new standard ... Lightning Labels more effectively meet its twin objectives of quality and ...
    (Date:8/4/2015)... ... August 04, 2015 , ... ... for executives and technology professionals in healthcare and technology markets, today announced significant ... Department of Defense’s recently-announced Electronic Health Record (EHR) decision. The DOD related numbers ...
    (Date:8/3/2015)... ... August 04, 2015 , ... ... an extensive line up of live courses for the month of August. , ... courses individually or by purchasing a Physical Therapy Flex package. Flex packages ...
    (Date:8/3/2015)... ... 03, 2015 , ... Zeiter’s Septic now performs septic installations ... and operated business, Zeiter’s Septic has been serving the community for over 20 ... because of their continued training and perseverance to provide their customers with new ...
    Breaking Medicine News(10 mins):Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4Health News:Lightning Labels Installs State-of-the-Art Digital Press 2Health News:Lightning Labels Installs State-of-the-Art Digital Press 3Health News:Coverage of DOD’s EHR Decision Reinforces Healthcare IT News’ Leadership 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 3Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 2Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 3
    ... San Francisco-to-Los Angeles ride May 31SAN FRANCISCO and LOS ... 41 states and 14 nations will stream out of ... Angeles as participants in the colorful and emotional AIDS/LifeCycle, ... expected to raise more than $10 million to support ...
    ... , , THURSDAY, May 28 (HealthDay News) -- A total ... motion in arthritic or deformed ankles has been approved ... Scandinavian Total Ankle Replacement (STAR) system is the first ... a surface of flexible plastic (polyethylene). , Total ankle ...
    ... PregnancyWHITE PLAINS, N.Y., May 28 Starting pregnancy at ... pregnancy is critical to giving a baby a healthy ... in response to new guidelines from the Institute of ... for the amount of weight a woman should gain ...
    ... in Independent CategoryNEW YORK, May 28 Prix ... development, has added a new recognition category to its 2009 ... Prix Galien USA are now being accepted at ... 1, 2009. For the first time, the Prix Galien USA ...
    ... Covers High-throughput, Anchorage-independent Assay for Screening Compounds for ... Falcon Genomics, Inc. announced today that it has ... the Company,s Cancer BioChip System (CBCS) for the ... a high-throughput in vitro setting with ...
    ... bacteria in the small intestine are both associated with ... in a new study in the June issue of ... & Sons on behalf of the American Association for ... also available online at Wiley Interscience ( www.interscience.wiley.com ). ...
    Cached Medicine News:Health News:AIDS/LifeCycle 8 to Raise $10+ Million to Fight AIDS 2Health News:AIDS/LifeCycle 8 to Raise $10+ Million to Fight AIDS 3Health News:Ankle Replacement System Lets Feet Move 2Health News:New Guidelines to Fight Obesity in Pregnancy Issued 2Health News:New Guidelines to Fight Obesity in Pregnancy Issued 3Health News:Prix Galien USA Now Accepting Nominations for Premiere Biopharmaceutical Industry Award 2Health News:Falcon Genomics Awarded Patent for Innovative Cancer Test 2Health News:Intestinal bacteria associated with non-alcoholic fatty liver disease 2
    Use the Mo Bio Vortex Adapter in conjunction with the Vortex Genie 2 for rapid bead beating procedures. Using the Mo Bio Vortex Adapter is an inexpensive alternative to other bead beating and Fast Pr...
    ... V-500 with Vacuum Controller V-800 and water-cooled secondary ... Model V-500 is a powerful ... vacuum applications. Applications Ideally suited ... Laboratory vacuum source for instruments including ...
    ... with Vacuum Controller V-800 Efficiently controls vacuum ... on and off as needed to maintain preset vacuum ... PTFE membrane vacuum pump designed to handle most vacuum ... with up to two rotary evaporators Laboratory ...
    ... BchiVac V-500 and water-cooled secondary condenser to ... a powerful PTFE membrane vacuum pump designed ... Ideally suited for use with ... Laboratory vacuum source for instruments including vacuum ...
    Medicine Products: